CoChat

Benzodiazepines: Uses, Dangers, and Clinical Considerations

Open access

The DOI matches its Crossref record; 78 of the 85 references it cites were found in a registry or an index; 35 of the 151 sources its claims cite were checked for support.

Abstract

Benzodiazepines (BZDs) are among one of the most widely prescribed drug classes in the United States. BZDs are a class of psychoactive drugs known for their depressant effect on the central nervous system (CNS). They quickly diffuse through the blood-brain barrier to affect the inhibitory neurotransmitter GABA and exert sedative effects. Related to their rapid onset and immediate symptom relief, BZDs are used for those struggling with sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, and epilepsy. One of the debilitating side effects of BZDs is their addictive potential. The dependence on BZDs generally leads to withdrawal symptoms, requiring careful tapering of the medication when prescribed. Regular use of BZDs has been shown to cause severe, harmful psychological and physical dependence, leading to withdrawal symptoms similar to that of alcohol withdrawal. Some of these withdrawal symptoms can be life threatening. The current treatment for withdrawal is through tapering with clonazepam. Many drugs have been tested as a treatment for withdrawal, with few proving efficacious in randomized control trials. Future research is warranted for further exploration into alternative methods of treating BZD withdrawal. This call to action proves especially relevant, as those seeking treatment for BZD dependence and withdrawal are on the rise in the United States.

Overview

CoChat Summary

TL;DR

This narrative review summarizes benzodiazepine indications, adverse effects, dependence, withdrawal, and clinical management, emphasizing that BZDs remain widely prescribed despite substantial risks. It concludes that gradual tapering with a long-acting BZD such as clonazepam is current withdrawal treatment, but evidence for many alternative therapies is mixed and further research is needed.

Key findings

  • BZDs are used for sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, epilepsy, catatonia, and alcohol/BZD withdrawal; chronic use is linked to tolerance, dependence, and potentially life-threatening withdrawal similar to alcohol withdrawal.
  • One cited study found a withdrawal rate of approximately 40% in people using long-acting BZDs for six or more months with abrupt cessation; another reported that the hazard of death was doubled in patients prescribed BZDs compared with controls, with 4 excess deaths in the anxiolytic group over an average of 7.6 years.
  • Among substance-using populations, 54% of oxycodone abusers were also dependent on a BZD, and 64% of heroin users were also abusing BZDs.
  • Withdrawal treatment evidence is mixed: a 7-day IV flumazenil infusion led to abstinence in over half of subjects in one study, propranolol still left 27–45% of patients with withdrawal symptoms in one study and approximately 80% in another severely dependent group, and oxcarbazepine shortened withdrawal to 11–19 days in an uncontrolled case series.

Methods

  • Design: narrative review of benzodiazepine pharmacology, clinical indications, dangers, misuse, withdrawal, and treatment.
  • Data/sample: no primary sample; the paper synthesizes published literature, including clinical studies, cohort studies, case reports, and reviews.
  • Main analysis: qualitative narrative synthesis of cited evidence, with no stated systematic search strategy, meta-analysis, or formal risk-of-bias assessment.

Limitations

  • The paper states that many drugs tested for BZD withdrawal have shown mixed results, with few proving efficacious in randomized controlled trials, and that no set taper schedule has been validated in the current literature.
  • The paper repeatedly notes limitations of cited studies, including small sample sizes, lack of double-blinding, uncontrolled designs, and potential underreporting of relapse.
  • Evident from the text: as a narrative review, it does not describe a systematic search, inclusion criteria, or quantitative synthesis, so its conclusions depend on the selected cited studies rather than a formal meta-analytic estimate.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/neurolint13040059

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

24 Valid · 11 Not valid · 111 Not checked · 13 Own results and interpretations

102 more claims · 22 with their cited sources checked

Create a free account to see all 159 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 48
  • Probably not a substantial claim. 3
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 78 references

Cited by

See all 340

Metadata

Authors
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D.
Affiliations
  • Louisiana State University (US)
  • University of the Pacific (US)
Corresponding author
Edinoff, Amber N.
Venue
Neurology International
Publisher
MDPI AG
Published
2021-11-10
Volume
13
Issue
4
Pages
594-607
ISSN
2035-8377 (ISSN-L)
OpenAlex
W3212918570
Cited by
340
References
85
Citations by year
2026: 96 · 2025: 102 · 2024: 91 · 2023: 43 · 2022: 8
FWCI
5.42
Type
journal article
Language
en
Open access
Locations
  • Neurology International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Scholarly Commons (University of the Pacific) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
Keywords
benzodiazepines, benzodiazepine dependence, benzodiazepine withdrawal, withdrawal symptoms, clonazepam, tapering, GABA, central nervous system depression, sleep disorders, anxiety, spasticity, epilepsy, drug addiction, alcohol withdrawal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benzodiazepines: Uses, Dangers, and Clinical Considerations. https://app.cochat.ai/papers/10.3390/neurolint13040059
The paper
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International. https://doi.org/10.3390/neurolint13040059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.